Home/Pipeline/Unnamed Joint Injection

Unnamed Joint Injection

Osteoarthritis

Discovery/PreclinicalActive

Key Facts

Indication

Osteoarthritis

Phase

Discovery/Preclinical

Status

Active

Company

Caliway Biopharmaceuticals

About Caliway Biopharmaceuticals

Caliway Biopharmaceuticals is a high-value, publicly traded biotech focused on developing breakthrough small-molecule drugs for aesthetic and chronic inflammatory conditions. Its core achievement is the development of CBL-514, a first-in-class injectable for localized fat reduction with a novel apoptosis mechanism, which has advanced into late-stage clinical trials. The company's strategy targets large, underserved markets where current treatments are inadequate, leveraging its proprietary platform and strategic base in Taiwan for global expansion.

View full company profile

Therapeutic Areas

Aesthetic Medicine Metabolic Disease Dermatology Rheumatology

Other Osteoarthritis Drugs

Drug	Company	Phase	Status
ViscoCell™ for Osteoarthritis	Likarda	Pre-clinical	Active
Osteoarthritis Biologic Therapy	Ageless Biotech	Phase 2b	Active
PKM-011	PK MED	Pre-clinical	Active
Osteoarthritis Program	OrthoSera	Pre-clinical	Active
CYT-108	Cytonics	Phase 2	Active
Topical PSGAG	ADORA Life Science	Pre-clinical	Active
FGF18 Gene Therapy	Remedium Bio	Pre-clinical	Active
MOTYS™	Doron Therapeutics	Phase 3	Active
Osteoarthritis Treatment Program	Biovico	Pre-clinical	Active
aGF	Scarcell Therapeutics	Phase 1	Active
Cartilage Repair	Sayenza Biosciences	Clinical	Active
4P004	4P-Pharma	Phase II	Active